Reported 9 months ago
On June 27, 2024, Taiwan Stock Exchange held a biotechnology-themed seminar where Xunlian (1784), Xunlian Genomics (4160), Hui Zhi (6615), and He Shi (1781), surged for the second day in a row. The companies benefited from the inclusion of 19 cancer tests under the National Health Insurance reimbursement scheme due to 'Next-Generation Sequencing' (NGS). Particularly, Hui Zhi hit a four-year high, closing at 74 yuan, while He Shi reached a yearly high at 21.45 yuan. The NGS business opportunities have significantly boosted Hui Zhi's stock price to a four-year high. Beyond the NGS advantage, with the passing of the 'Biopharmaceutical Dual Laws' in early June, various industries are actively entering the extracellular vesicle sector, and Xunlian Group has long been involved in vesicle research for skin, hair, and medical beauty markets, expanding its production capacity continuously. Xunlian's stock has surged by 96% since hitting a low of 58.8 yuan on April 19, now closing at 115.5 yuan. Xunlian Genomics, on the other hand, broke through the 100-yuan mark to close at 109.5 yuan, a remarkable increase of 118%. Cancer patients can now identify gene mutation sites through NGS before treatment, enabling precision therapy. Hui Zhi, with years of experience in genetic testing, is the first company in Taiwan to introduce Roche's latest NGS fully automated equipment, simplifying over 100 steps for efficient operation. He Shi, a manufacturer of precision medical devices such as blood pressure monitors and glucose meters for many renowned international clients, also hit a yearly high closing at 21.45 yuan today. FTNN News Network reminds investors that this information is for reference only, and they should make independent judgments and evaluations.
Source: YAHOO